癌症免疫治療市場，依治療類型、依給藥途徑、依癌症類型、依配銷通路、依地理位置

預計2024年全球癌症免疫治療市場價值為1,410.6億美元，預計到2031年將達到3,145.3億美元，2024年至2031年年複合成長率（CAGR）為12.1%。

圖 1. 2024 年癌症免疫治療市場佔有率 (%)（依地區）

癌症免疫療法是一種利用人體自體免疫系統對抗癌症的癌症治療方法。這是一種創新方法，利用免疫系統的力量並對其進行修改，以增強人體對癌症的自然防禦能力。癌症免疫療法包括單株抗體、檢查點抑制劑、白血球介素抑制劑、治療性癌症疫苗等療法。隨著最近的科學突破提高了對腫瘤細胞與免疫系統之間複雜相互作用的理解，它越來越受到重視。癌症免疫療法代表了一種新穎的治療模式，有可能改變未來癌症的治療方式。

市場動態：

全球癌症免疫治療市場的成長是由以下因素推動的：全球癌症盛行率不斷上升、對有效標靶治療的需求不斷成長以及與傳統治療方式相比，癌症免疫治療相關的治療成功率更高。癌症仍然是死亡的主要原因之一，預計全球癌症負擔在不久的將來將大幅上升。這極大地促進了免疫療法的採用。生物技術的進步以及對癌症免疫學的更好理解促使了新型免疫療法的發展，這為改善患者的治療結果鋪平了道路。然而，與免疫療法藥物相關的高成本、對專業基礎設施和醫護人員的需求以及與免疫治療相關的安全問題是限制市場成長的一些課題。該領域針對新癌症類型的積極研發以及正在進行的臨床試驗有可能為市場參與者提供成長機會。

研究的主要特點：

• 該報告對全球癌症免疫治療市場進行了深入分析，並提供了以2023年為基準年的預測期（2024-2031）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它闡明了不同區隔市場的潛在收入機會，並解釋了該市場有吸引力的投資主張矩陣。
• 這項研究還提供了有關市場促進因素、限制因素、機會、新產品發布或批准、市場趨勢、區域前景以及主要參與者採取的競爭策略的重要見解。
• 它根據以下參數描述了全球癌症免疫治療市場的主要參與者——公司亮點、產品組合、主要亮點、財務表現和策略。
• 該報告的見解將使行銷人員和公司管理當局能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球癌症免疫治療市場報告迎合了該行業的各個利益相關者，包括投資者、供應商、產品製造商、分銷商、新進業者和財務分析師。
• 利害關係人可以透過用於分析全球癌症免疫治療市場的各種策略矩陣輕鬆做出決策。

目錄

第1章：研究目標與假設

• 研究目標
• 假設
• 縮寫

第 2 章：市場範圍

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map (COM)

第 3 章：市場動態、法規與趨勢分析

• 市場動態
  • 促進要素
  • 限制
  • 市場機會
• 影響分析
• 市場走向
• 最近的發展
• 收購和合作場景
• 技術概覽
• 監管場景
• 定價分析
• PEST分析

第 4 章：全球癌症免疫治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第 5 章：全球癌症免疫治療市場，依治療類型，2019 - 2031 年（十億美元）

• 概述
• 免疫檢查點抑制劑
• 疫苗
• 預防疫苗
• 治療性疫苗
• 過繼性細胞療法
• 腫瘤浸潤淋巴細胞（TIL）療法
• CAR T細胞療法
• 工程 T 細胞受體 (TCR) 療法
• 自然殺手（NK）細胞療法
• 免疫系統調節劑
• 干擾素
• 免疫調節劑 (IMiD)
• 白血球介素
• 單株抗體
• 裸單株抗體
• 綴合單株抗體
• 雙特異性單株抗體
• 溶瘤病毒治療

第 6 章：全球癌症免疫治療市場，依給藥途徑分類，2019 - 2031 年（十億美元）

• 概述
• 皮下
• 口服
• 肌肉注射
• 靜脈注射 (IV)
• 其他

第 7 章：全球癌症免疫治療市場，依癌症類型，2019 - 2031 年（十億美元）

• 概述
• 淋巴瘤
• 乳癌
• 大腸直腸癌
• 膀胱癌
• 皮膚癌
• 肺癌
• 腎癌
• 其他

第 8 章：全球癌症免疫治療市場，依配銷通路，2019 - 2031 年（十億美元）

• 概述
• 醫院藥房
• 零售藥局
• 網路藥局

第 9 章：2019 - 2031 年全球癌症免疫治療市場（依地區）（十億美元）

• 介紹
• 北美洲
• 美國
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地區
• 歐洲
• 英國
• 德國
• 義大利
• 法國
• 西班牙
• 俄羅斯
• 歐洲其他地區
• 亞太地區
• 中國
• 印度
• 日本
• 東協
• 澳洲
• 韓國
• 亞太地區其他地區
• 中東
• 海灣合作理事會
• 以色列
• 中東其他地區
• 非洲
• 北非
• 中非
• 南非

第 10 章：競爭格局

• 公司簡介
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

第 11 章：分析師建議

• 命運之輪
• 分析師觀點
• 連貫的機會圖

第 12 章：參考文獻與研究方法

• 參考
• 研究方法論

Global cancer immunotherapy market is estimated to be valued at USD 141.06 Bn in 2024 and is expected to reach USD 314.53 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.

Figure 1.Cancer Immunotherapy Market Share (%), By Region, 2024

Cancer immunotherapy is a type of cancer treatment that utilizes the body's own immune system to fight against cancer. It is an innovative approach that harnesses the power of the immune system and modifies it to enhance the body's natural defenses against cancer. Cancer immunotherapy comprises therapies like monoclonal antibodies, checkpoint inhibitors, interleukin inhibitors, therapeutic cancer vaccines and others. It is gaining prominence as recent scientific breakthroughs have improved understanding of the complex interaction between tumor cells and the immune system. Cancer immunotherapy represents a novel treatment paradigm that has the potential to transform the way cancer is treated in the future.

Market Dynamics:

Global cancer immunotherapy market growth is driven by factors such as increasing prevalence of cancer worldwide, rising demand for effective targeted therapies, and higher treatment success rates associated with cancer immunotherapy as compared to conventional treatment modalities. Cancer remains one of the leading causes of mortality and the global burden of cancer is expected to rise significantly in the near future. This is providing a major boost to immunotherapy adoption. Advancements in biotechnology along with better understanding of cancer immunology have led to the development of novel immunotherapies, which are paving the way for improved patient outcomes. However, high costs associated with immunotherapy drugs, need for specialized infrastructure and healthcare personnel, and safety concerns related to immunotherapy are some of the challenges restraining the market growth. Active R&D in this field, targeting new cancer types, and ongoing clinical trials hold potential to provide growth opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global cancer immunotherapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, and Incyte.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cancer immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer immunotherapy market.

Detailed Segmentation-

• Therapy Type:
  • Immune checkpoint inhibitors
  • Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
  • Adoptive Cell Therapies
  • Tumor-infiltrating lymphocyte (TIL) therapy
  • CAR T-cell therapy
  • Engineered T-cell receptor (TCR) therapy
  • Natural killer (NK) cell therapy
  • Immune System Modulators
  • Interferons
  • Immunomodulators (IMiDs)
  • Interleukins
  • Monoclonal antibodies
  • Naked monoclonal antibodies
  • Conjugated monoclonal antibodies
  • Bispecific monoclonal antibodies
  • Oncolytic Virus Therapy
• Route of Administration:
  • Subcutaneous
  • Oral
  • Intramuscular
  • Intravenous (IV)
  • Others
• Cancer Type:
  • Lymphoma
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Skin Cancer
  • Lung Cancer
  • Kidney Cancer
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Cancer Immunotherapy Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Cancer Immunotherapy Market, By Therapy Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Immune checkpoint inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Preventive Vaccines
• Therapeutic Vaccines
• Adoptive Cell Therapies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Tumor-infiltrating lymphocyte (TIL) therapy
• CAR T-cell therapy
• Engineered T-cell receptor (TCR) therapy
• Natural killer (NK) cell therapy
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Interferons
• Immunomodulators (IMiDs)
• Interleukins
• Monoclonal antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Oncolytic Virus Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Cancer Immunotherapy Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intramuscular
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous (IV)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Cancer Immunotherapy Market, By Cancer Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Skin Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Kidney Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Cancer Immunotherapy Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Cancer Immunotherapy Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Gilead Sciences, Inc.
• Company Overview
• Product Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact